




# Psoriasis Awareness Month

Aug 2024





# Psoriasis is twice as prevalent in Caucasians compared to African Americans

- 2-3% of the total population (125M people worldwide and 8M Americans) have psoriasis.
- Psoriasis is likely to be underdiagnosed among African-Americans and other individuals with skin of color due to differences in clinical presentation.













# Psoriasis is NOT a cosmetic problem

- Individuals with psoriasis experience higher rates of many comorbidities, including cardiovascular disease, heart attack, stroke, metabolic syndrome, and depression, among others.
  - Nearly 40 percent with psoriatic arthritis reported their disease to be a large problem in everyday life
  - Nearly 60% of people with psoriasis reported their disease to be a large problem in their everyday life



# Research to find a cure for psoriasis and psoriatic arthritis is ongoing

- According to [clinicaltrials.gov](https://clinicaltrials.gov), more than 200 clinical trials, associated with psoriasis, are currently recruiting for patients
- T helper 17 (TH17)/interleukin-17 (IL-17) pathway has a major role in the pathogenesis of psoriasis
- IL-17, IL-23, tumour necrosis factor (TNF), and tyrosine kinase 2 (TYK2) are key targets for therapy

Drug	Company	Mode of action	Highest phase
Deucravacitinib	 Bristol Myers Squibb®	Oral TYK2 inhibitor	Approved
Bimekizumab	 Ucb Pharma	Injectable IL-17A/F inhibitor	Approved
TAK-279	 Takeda	Oral TYK2 inhibitor	Phase III
Orismilast	 UNION THERAPEUTICS	Oral PDE4 inhibitor	Phase II
ME3183	 meiji	Oral PDE4 inhibitor	Phase II
JNJ-2113	 Janssen <small>PHARMACEUTICAL COMPANIES OF Johnson &amp; Johnson</small>	Oral IL-23 receptor inhibitor	Phase II
DC-806	 Lilly	Oral IL-17 inhibitor	Phase II
DC-853		Oral IL-17 inhibitor	Phase I
TLL018-205	 高光制藥 HIGHLIGHT PHARMA	Oral TYK2/JAK1 inhibitor	Phase II

Selected therapies for psoriasis; IL, interleukin; JAK, Janus kinase; PDE4, phosphodiesterase 4; TYK2, tyrosine kinase 2.

# How can we help...



At [GlintLab](#), we support scientists and researchers in the early discovery and preclinical stages by offering advanced histopathology services to enhance the understanding and treatment of psoriasis and other inflammatory or autoimmune diseases.

How can histopathology help in research and discovery that is introducing new treatment options, including biologic drugs, JAK inhibitors, gene therapy, and novel topical treatments:

- **Assay Optimization:** Enhance sensitivity and specificity for key psoriasis biomarkers like CD3, CD4, CD8, Ki-67, TNF- $\alpha$ , IL-17, IL-22, and CD11c.
- **RNA ISH:** Detect and quantify gene expression in skin tissues.
- **Dual ISH-IHC:** Combine RNA and protein analysis for comprehensive insights.
- **Skin Layer Analysis and Segmentation:** Quantifying biomarker expression within different skin layers.
- **Spatial Data Analysis:** Explore spatial relationships and cell interactions in psoriatic lesions.
- **Data Interpretation and Reporting:** Comprehensive data interpretation, including statistical analysis and visual data representation.



## Connect with Us:

✉ [scientist@glintlab.com](mailto:scientist@glintlab.com)

🔗 <https://glintlab.com/>

📍 6324 Ferris Square, Unit C San Diego, CA 92121

☎ 9494781160

